Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06902376 · ClinicalTrials.gov registry record · Phase 1
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
A Phase 1 study of Thyroid Cancer and Anaplastic Thyroid Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT06902376 is a Phase 1 study of Thyroid Cancer and Anaplastic Thyroid Cancer that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 12 participants, below the 282-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06902376, a Phase 1 study of Thyroid Cancer and Anaplastic Thyroid Cancer, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF mutation (BRAF V600E).
Conditions Studied
Interventions
- BIOLOGICAL Cemiplimab
- DRUG XL092
Study Locations (2)
Massachusetts
- Dana Farber/Harvard Cancer Center - Boston
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-06-03 |
| Est. Completion | 2028-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06902376
The ClinicalTrials.gov registry entry for NCT06902376 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 282-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (96% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.
NCT06902376 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06902376 about?
NCT06902376 is a clinical study titled "XL092 and Cemiplimab in BRAF WT Thyroid Cancer". This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF mutation (BRAF V600E).
What is the current status of trial NCT06902376?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-06-03. Estimated completion is 2028-08-31.
What conditions does trial NCT06902376 study?
This clinical trial studies the following conditions: Thyroid Cancer, Anaplastic Thyroid Cancer, BRAF Mutation-Related Tumors.
What interventions are being tested in trial NCT06902376?
The interventions under investigation include: Cemiplimab (BIOLOGICAL), XL092 (DRUG).
Who is sponsoring clinical trial NCT06902376?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06902376 being conducted?
This trial has 2 study locations across Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
SLV-154 Treatment of Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
RECRUITING · Phase 1
-
TH1902 in Patients With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.